Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real‐world study

Abstract

A high proportion of patients presented severe infections during follow-up, with non-negligible attributable mortality, but infection incidence is not superior to the one observed during the chemotherapy era. In selected cases with specific risk factors for infection, antimicrobial prophylaxis should be considered.